Skip to main content

Table 2 Response, remission and low disease activity rates by treatment arm at week 30 (pooled data)

From: Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

n/N (%) Reference IFX IV CT-P13 IV CT-P13 SC
Patients achieving a EULAR good response (CRP criteria) 98/259 (37.8%) 165/415 (39.8%) 83/157 (52.9%)
Patients achieving ACR20 response 179/261 (68.6%) 318/418 (76.1%) 142/161 (88.2%)
Patients achieving ACR50 response 103/261 (39.5%) 195/418 (46.7%) 106/161 (65.8%)
Patients achieving ACR70 response 47/261 (18.0%) 97/418 (23.2%) 68/161 (42.2%)
DAS28-CRP
 Patients achieving low disease activity: DAS28-CRP ≤ 3.2 101/259 (39.0%) 166/415 (40.0%) 84/157 (53.5%)
 Patients achieving remission: DAS28-CRP < 2.6 60/259 (23.2%) 101/415 (24.3%) 59/157 (37.6%)
CDAI
 Patients achieving low disease activity: CDAI ≤ 10.0 93/259 (35.9%) 172/416 (41.3%) 92/161 (57.1%)
 Patients achieving remission: CDAI ≤ 2.8 22/259 (8.5%) 50/416 (12.0%) 27/161 (16.8%)
SDAI
 Patients achieving low disease activity: SDAI ≤ 11.0 96/259 (37.1%) 172/415 (41.4%) 89/157 (56.7%)
 Patients achieving remission: SDAI ≤ 3.3 22/259 (8.5%) 53/415 (12.8%) 29/157 (18.5%)
Patients achieving Boolean remission 6/260 (2.3%) 12/416 (2.9%) 12/161 (7.5%)
Patients achieving HAQ-DI MCID (≥ 0.22) 15/261 (5.7%) 36/418 (8.6%) 30/161 (18.6%)
  1. ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, EULAR European League Against Rheumatism, HAQ-DI Health Assessment Questionnaire–Disability Index, IFX infliximab, IV intravenous, MCID minimal clinically important difference, SC subcutaneous, SDAI Simple Disease Activity Index